Vaishali Pharma has initiated the registration of 30 products in the Central African Countries with the portfolio of Antibiotics, Sedatives, Anti-Malaria, Anti-Inflammatory, Painkillers and Multi-Vitamins. These products have a good demand in the markets of Central African Countries.
Atul Arvind Vasani, Chairman and Managing Director of the Company says that: “ the Company has initiated with the registration of 30 products in the Central African Countries with the portfolio of Antibiotics, Sedatives, Anti-Malaria, Anti-Inflammatory, Painkillers and it's yet another important step towards laying a strong foundation and meeting our desired targets. Our Company is in a phase of evolution and growth and we will strive hard and deliver on the expected lines."
On Friday, the company highlighted that this remarkable achievement, enables the Company to strengthen its presence in the high growth market of Central African Countries and entitles the Company to reach out to more and more territories. The company also plans to register a similar range of products in the neighbouring countries.
According to the value of Africa’s pharmaceutical industry jumped to $20.8 billion in 2013 from just $4.7 billion a decade earlier. This growth is constantly progressing at a rapid pace and experts predict that the market will be worth $40 billion to $65 billion by 2020 and so on.
At around 1.56 pm, Vaishali Pharma was trading at Rs33.95 per piece up by 2.6% on NSE.